Primary amino-bisphosphonates: A new class of gastrotoxic drugs- Comparison of alendronate and aspirin

D. Y. Graham, H. M. Malaty, R. Goodgame

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Background: Alendronate and pamidronate are primary amino- bisphosphonates used in the treatment of metabolic bone disease. Both drugs have been associated with reversible erosive esophagitis and as a result pamidronate is approved in the United States only for parenteral use. In rats, alendronate causes acute gastric mucosal damage similar to that seen with aspirin or nonsteroidal anti-inflammatory drugs. Methods: We performed a blinded, crossover, randomized, single-center, placebo-controlled, endoscopic comparison of alendronate (40 mg/day), aspirin (1, 300 mg/day), and placebo to evaluate the presence and degree of mucosal damage to the esophagus, stomach, and duodenal bulb. Results: Twelve normal healthy volunteers were studied both before and after 4 days of drug therapy. Placebo caused no visible endoscopic damage. In contrast, both aspirin and alendronate were associated with visible gastric mucosal injury in the majority of those studied (75 and 58%, respectively) and both were significantly greater than placebo (p < 0.001). The gastric mucosal injury was deemed severe in 50% of those receiving alendronate or aspirin; one alendronate-associated gastric ulcer was seen. Esophageal and duodenal bulb injury was seen once each, and both were associated with alendronate. Conclusions: The primary amino- bisphosphonate alendronate causes mucosal injury to the upper gastrointestinal tract similar to aspirin. Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution.

Original languageEnglish (US)
Pages (from-to)1322-1325
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume92
Issue number8
StatePublished - 1997
Externally publishedYes

Fingerprint

Alendronate
Diphosphonates
Aspirin
pamidronate
Pharmaceutical Preparations
Stomach
Placebos
Wounds and Injuries
Healthy Volunteers
Upper Gastrointestinal Tract
Esophagitis
Metabolic Bone Diseases
Stomach Ulcer
Esophagus
Anti-Inflammatory Agents
Drug Therapy

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Primary amino-bisphosphonates : A new class of gastrotoxic drugs- Comparison of alendronate and aspirin. / Graham, D. Y.; Malaty, H. M.; Goodgame, R.

In: American Journal of Gastroenterology, Vol. 92, No. 8, 1997, p. 1322-1325.

Research output: Contribution to journalArticle

@article{246e969a27fb467c9fafc4538a543a88,
title = "Primary amino-bisphosphonates: A new class of gastrotoxic drugs- Comparison of alendronate and aspirin",
abstract = "Background: Alendronate and pamidronate are primary amino- bisphosphonates used in the treatment of metabolic bone disease. Both drugs have been associated with reversible erosive esophagitis and as a result pamidronate is approved in the United States only for parenteral use. In rats, alendronate causes acute gastric mucosal damage similar to that seen with aspirin or nonsteroidal anti-inflammatory drugs. Methods: We performed a blinded, crossover, randomized, single-center, placebo-controlled, endoscopic comparison of alendronate (40 mg/day), aspirin (1, 300 mg/day), and placebo to evaluate the presence and degree of mucosal damage to the esophagus, stomach, and duodenal bulb. Results: Twelve normal healthy volunteers were studied both before and after 4 days of drug therapy. Placebo caused no visible endoscopic damage. In contrast, both aspirin and alendronate were associated with visible gastric mucosal injury in the majority of those studied (75 and 58{\%}, respectively) and both were significantly greater than placebo (p < 0.001). The gastric mucosal injury was deemed severe in 50{\%} of those receiving alendronate or aspirin; one alendronate-associated gastric ulcer was seen. Esophageal and duodenal bulb injury was seen once each, and both were associated with alendronate. Conclusions: The primary amino- bisphosphonate alendronate causes mucosal injury to the upper gastrointestinal tract similar to aspirin. Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution.",
author = "Graham, {D. Y.} and Malaty, {H. M.} and R. Goodgame",
year = "1997",
language = "English (US)",
volume = "92",
pages = "1322--1325",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Primary amino-bisphosphonates

T2 - A new class of gastrotoxic drugs- Comparison of alendronate and aspirin

AU - Graham, D. Y.

AU - Malaty, H. M.

AU - Goodgame, R.

PY - 1997

Y1 - 1997

N2 - Background: Alendronate and pamidronate are primary amino- bisphosphonates used in the treatment of metabolic bone disease. Both drugs have been associated with reversible erosive esophagitis and as a result pamidronate is approved in the United States only for parenteral use. In rats, alendronate causes acute gastric mucosal damage similar to that seen with aspirin or nonsteroidal anti-inflammatory drugs. Methods: We performed a blinded, crossover, randomized, single-center, placebo-controlled, endoscopic comparison of alendronate (40 mg/day), aspirin (1, 300 mg/day), and placebo to evaluate the presence and degree of mucosal damage to the esophagus, stomach, and duodenal bulb. Results: Twelve normal healthy volunteers were studied both before and after 4 days of drug therapy. Placebo caused no visible endoscopic damage. In contrast, both aspirin and alendronate were associated with visible gastric mucosal injury in the majority of those studied (75 and 58%, respectively) and both were significantly greater than placebo (p < 0.001). The gastric mucosal injury was deemed severe in 50% of those receiving alendronate or aspirin; one alendronate-associated gastric ulcer was seen. Esophageal and duodenal bulb injury was seen once each, and both were associated with alendronate. Conclusions: The primary amino- bisphosphonate alendronate causes mucosal injury to the upper gastrointestinal tract similar to aspirin. Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution.

AB - Background: Alendronate and pamidronate are primary amino- bisphosphonates used in the treatment of metabolic bone disease. Both drugs have been associated with reversible erosive esophagitis and as a result pamidronate is approved in the United States only for parenteral use. In rats, alendronate causes acute gastric mucosal damage similar to that seen with aspirin or nonsteroidal anti-inflammatory drugs. Methods: We performed a blinded, crossover, randomized, single-center, placebo-controlled, endoscopic comparison of alendronate (40 mg/day), aspirin (1, 300 mg/day), and placebo to evaluate the presence and degree of mucosal damage to the esophagus, stomach, and duodenal bulb. Results: Twelve normal healthy volunteers were studied both before and after 4 days of drug therapy. Placebo caused no visible endoscopic damage. In contrast, both aspirin and alendronate were associated with visible gastric mucosal injury in the majority of those studied (75 and 58%, respectively) and both were significantly greater than placebo (p < 0.001). The gastric mucosal injury was deemed severe in 50% of those receiving alendronate or aspirin; one alendronate-associated gastric ulcer was seen. Esophageal and duodenal bulb injury was seen once each, and both were associated with alendronate. Conclusions: The primary amino- bisphosphonate alendronate causes mucosal injury to the upper gastrointestinal tract similar to aspirin. Even when used according to manufacturer's dosing instructions alendronate should probably be used with caution.

UR - http://www.scopus.com/inward/record.url?scp=0030802835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030802835&partnerID=8YFLogxK

M3 - Article

C2 - 9260798

AN - SCOPUS:0030802835

VL - 92

SP - 1322

EP - 1325

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 8

ER -